Knight Therapeutics (TSE:GUD) Reaches New 52-Week High – Time to Buy?

Knight Therapeutics Inc. (TSE:GUD)’s stock price hit a new 52-week high during trading on Monday . The stock traded as high as C$9.74 and last traded at C$9.74, with a volume of 23150 shares. The stock had previously closed at C$9.45.

Analyst Upgrades and Downgrades

Separately, Canaccord Genuity Group set a C$9.50 price objective on shares of Knight Therapeutics and gave the stock a “buy” rating in a research note on Friday, May 8th. One investment analyst has rated the stock with a Buy rating, According to data from MarketBeat, Knight Therapeutics currently has a consensus rating of “Buy” and an average price target of C$9.50.

Knight Therapeutics Stock Performance

The firm has a market capitalization of C$967.06 million, a price-to-earnings ratio of 164.17, a P/E/G ratio of -1,013.50 and a beta of -0.14. The stock’s fifty day moving average is C$8.51 and its two-hundred day moving average is C$7.12. The company has a quick ratio of 1.79, a current ratio of 2.32 and a debt-to-equity ratio of 8.86.

Knight Therapeutics (TSE:GUD) last announced its quarterly earnings results on Thursday, May 7th. The company reported C$0.13 EPS for the quarter. Knight Therapeutics had a net margin of 1.10% and a return on equity of 0.73%. The firm had revenue of C$147.59 million during the quarter. On average, analysts predict that Knight Therapeutics Inc. will post 0.1009486 earnings per share for the current year.

About Knight Therapeutics

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company’s principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.